[CAS NO. 4291-63-8] Cladribine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [4291-63-8]

Catelog

HY-13599

Brand

MCE

CAS

4291-63-8

DESCRIPTION [4291-63-8]

Overview

MDL	MFCD00153939
Molecular Weight	285.69
Molecular Formula	C10H12ClN5O3
SMILES	OC[C@H]1O[C@@H](N2C=NC3=C2N=C(N=C3N)Cl)C[C@@H]1O

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis ^[1] ^[2] .

IC50 & Target

Adenosine deaminase ^[2]

In Vitro

Cladribine (0.25-4 μM; 24-48 hours) inhibits human DLBCL cells proliferation ^[1] .
Cladribine (1-4 μM; 24 hours) induces G1 phase arrest via decreasing the expressions of Cyclin D1 and Cyclin E, and increasing the expressions of p21 and p27 in DLBCL cells ^[1] .
Cladribine (1-4 μM; 24 hours) induces apoptosis and activates extrinsic and intrinsic signaling pathways in human DLBCL cells ^[1] .
Cladribine (1-4 μM; 24 hours) activates endoplasmic reticulum stress ^[1] .
Cladribine inhibits cell proliferation of multiple myeloma (MM) cells in a dose-dependent manner; with IC ₅₀ s of approximately 2.43 μM, 0.75 μM and 0.18 μM for U266, RPMI8226 and MM1.S cells, respectively ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay ^[1]

Cell Line:	The human DLBCL cell lines (U2932, OCI-LY10, SUDHL2, WSU-DLCL2, DB)
Concentration:	0 μM, 0.25 μM, 0.5 μM, 1 μM, 2 μM, 4 μM
Incubation Time:	24 hours, 48 hours
Result:	Exhibited notable suppression of cell proliferation in five DLBCL cells.

Western Blot Analysis ^[1]

Cell Line:	U2932 cells, WSU-DLCL2 cells
Concentration:	0 μM, 1 μM, 2 μM, 4 μM
Incubation Time:	24 hours
Result:	Decreased the expressions of Cyclin D1 and Cyclin E, and increased the expressions of p21 and p27.

Apoptosis Analysis ^[1]

Cell Line:	U2932 cells, WSU-DLCL2 cells
Concentration:	0 μM, 1 μM, 2 μM, 4 μM
Incubation Time:	24 hours
Result:	Induced apoptosis and activates exogenous and endogenous apoptotic signaling pathways.

Cell Cycle Analysis ^[1]

Cell Line:	U2932 cells, WSU-DLCL2 cells
Concentration:	0 μM, 1 μM, 2 μM, 4 μM
Incubation Time:	24 hours
Result:	Caused G1 phase arrest.

RT-PCR ^[1]

Cell Line:	U2932 cells, WSU-DLCL2 cells
Concentration:	0 μM, 1 μM, 2 μM, 4 μM
Incubation Time:	24 hours
Result:	Activated ER stress.

In Vivo

Cladribine (10 μg/kg; i.p.; 3 times/week; for 2 weeks) may have benefits in the treatment of ischemia/reperfusion injury to the biochemical and histopathologic parameters ^[3] .
Cladribine (0.5 mg/kg; i.p.; daily; for 60 days) increases amyloid beta peptide generation and plaque burden in APdE9 mice ^[4] .
Cladribine exhibits C _max (rat 4.9 ng/mL) following intra-arterial injection ^[5] .
Cladribine exhibits C _max (rat 1.1 ng/mL) following subcutaneous injection ^[5] .
Cladribine exhibits elimination half-lives (rat 3.5 h) and plasma clearance (rat 2.8 L/h/kg) following intra-arterial injection ^[5] .
Cladribine exhibits elimination half-lives (rat 4.5 h) and plasma clearance (rat 2.3 L/h/kg) following subcutaneous injection ^[5] .
Cladribine administration with s.c. injection may produce more favourable pharmacokinetic profiles than i.a. injection following a single dose ^[5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats, ischemic injury model ^[3]
Dosage:	10 μg/kg
Administration:	Intraperitoneal injection, 3 times/week, for 2 weeks
Result:	Might increase expression of Sphk1 and consecutively SphK1 suppressed HIF-1α.

Animal Model:	Male Sprague Dawley rats (350-450 g) ^[5]
Dosage:	2 mg/kg for s.c., 1 mg/kg for i.a. (Pharmacokinetic Analysis)
Administration:	Subcutaneous injection, intra-arterial
Result:	C _max (4.9 ng/mL i.a.; 1.1 ng/mL s.c.), T _1/2 β (3.5 h i.a.; 4.5 s.c.).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04195945	Fred Hutchinson Cancer Center\|Jazz Pharmaceuticals	Acute Myeloid Leukemia\|Myeloid Neoplasm	March 11, 2020	Phase 2
NCT04550455	Keith Edwards, M.D.\|EMD Serono\|Multiple Sclerosis Center of Northeastern New York	Multiple Sclerosis	September 16, 2020	Phase 4
NCT03477500	Haukeland University Hospital	Multiple Sclerosis	March 21, 2018	Phase 3
NCT02756572	University of Washington\|National Cancer Institute (NCI)	Blasts 10 Percent or More of Bone Marrow Nucleated Cells\|Chronic Myelomonocytic Leukemia-2\|High Grade Malignant Neoplasm\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts-2\|Myeloid Neoplasm\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	September 22, 2016	Phase 2
NCT04708054	M.D. Anderson Cancer Center	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome	October 21, 2021	Phase 2
NCT04676204	Monash University	Multiple Sclerosis\|Adherence, Medication	September 25, 2020
NCT05313958	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Third Affiliated Hospital, Sun Yat-Sen University\|Maternal and Child Health Hospital of Foshan\|The First Affiliated Hospital of Guangzhou Medical University\|Second Xiangya Hospital of Central South University\|Jiangxi Province Children´s Hospital\|Southern Medical University, China\|The First Affiliated Hospital of Nanchang University\|Guangzhou First People´s Hospital\|First Affiliated Hospital of Shantou University Medical College	Leukemia, Monocytic, Acute\|Pediatric AML	December 1, 2021	Phase 2\|Phase 3
NCT02044796	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Acute Biphenotypic Leukemia\|de Novo Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	January 23, 2014	Phase 1\|Phase 2
NCT04640818	Claudio Gobbi\|Merck AG Switzerland\|Ospedale Civico, Lugano	Multiple Sclerosis	December 17, 2020
NCT02131753	University of Giessen	Hairy Cell Leukemia	May 2004	Phase 2\|Phase 3
NCT00199030	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia T-Cell\|Lymphoma, Lymphoblastic	February 2004	Phase 2
NCT00718549	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	July 21, 2009	Phase 3
NCT01446900	European Institute of Oncology	Chronic Lymphocytic Leukaemia\|Small Lymphocytic Lymphoma	January 2011	Phase 2
NCT00213135	EMD Serono	Multiple Sclerosis, Relapsing-Remitting	April 2005	Phase 3
NCT03531918	Fred Hutchinson Cancer Center\|Pfizer	Acute Myeloid Leukemia	September 14, 2018	Phase 1\|Phase 2
NCT04797767	University of Washington\|AbbVie	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|Mixed Phenotype Acute Leukemia\|Myeloid Neoplasm\|Relapsed Acute Biphenotypic Leukemia\|Relapsed Acute Myeloid Leukemia\|Relapsed Mixed Phenotype Acute Leukemia\|Relapsed Myeloid Neoplasm\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Mixed Phenotype Acute Leukemia\|Refractory Myeloid Neoplasm	February 4, 2022	Phase 1
NCT00787969	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	April 2009	Phase 1
NCT04254640	Sun Yat-sen University	Acute Myeloid Leukemia\|Elderly Patients\|Newly Diagnosed	March 1, 2021	Phase 2
NCT03586609	M.D. Anderson Cancer Center	Acute Myeloid Leukemia	October 25, 2018	Phase 2
NCT05365035	M.D. Anderson Cancer Center	Myelodysplastic Syndromes\|Myeloproliferative Chronic Myelomonocytic Leukemia	September 23, 2022	Phase 2
NCT02096055	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Untreated Adult Acute Myeloid Leukemia	April 4, 2014	Phase 2
NCT00258271	University of Rochester	Leukemia	March 2005	Phase 1
NCT03589729	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Blasts 10 Percent or More of Bone Marrow Nucleated Cells\|High Risk Myelodysplastic Syndrome\|Myeloid Sarcoma\|Myeloproliferative Neoplasm\|Philadelphia Chromosome Positive	September 19, 2018	Phase 2
NCT00072007	Swiss Group for Clinical Cancer Research	Leukemia	June 2002	Phase 2
NCT02115295	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Blasts 10 Percent or More of Bone Marrow Nucleated Cells\|Blasts 10 Percent or More of Peripheral Blood White Cells\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	May 19, 2014	Phase 2
NCT04934800	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany\|Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany	Multiple Sclerosis	December 10, 2019
NCT02157181	Jurgen Barth\|University of Giessen	Hairy Cell Leukemia (HCL)	June 2004	Phase 2
NCT01473797	Assistance Publique - Hôpitaux de Paris	Langerhans Cell Histiocytosis of Lung	November 2011	Phase 2
NCT04178005	University of Texas Southwestern Medical Center\|EMD Serono	Multiple Sclerosis	February 19, 2020	Phase 4
NCT04121403	Oslo University Hospital\|University of Oslo\|Göteborg University\|Sykehuset Ostfold\|Sykehuset Telemark\|Vestre Viken Hospital Trust\|Sorlandet Hospital HF\|Helse Stavanger HF\|Sykehuset Innlandet HF\|Sykehuset i Vestfold HF\|Helse Forde\|University Hospital of North Norway\|St. Olavs Hospital	Relapsing Multiple Sclerosis\|Multiple Sclerosis	October 16, 2019	Phase 3
NCT04880746	Ruijin Hospital\|Xinqiao Hospital of Chongqing\|The First Affiliated Hospital of Anhui Medical University\|Harbin Hematology and Oncology Institute\|The Affiliated Zhongshan Hospital of Dalian University\|Qilu Hospital of Shandong University\|Fujian Medical University Union Hospital\|Shanxi Province Cancer Hospital\|RenJi Hospital\|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine\|Huashan Hospital	Peripheral T-cell Lymphoma	October 17, 2020	Phase 3
NCT00412594	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hairy Cell Leukemia\|Recurrent Hairy Cell Leukemia	June 10, 2004	Phase 2
NCT01602939	Hospital Virgen de la Salud	Systemic Mastocytosis	May 2012	Phase 2\|Phase 3
NCT03012672	University of Washington\|National Cancer Institute (NCI)	Acute Leukemia of Ambiguous Lineage\|Acute Myeloid Leukemia\|Myeloid Neoplasm	December 30, 2016	Phase 2
NCT01515527	M.D. Anderson Cancer Center	Leukemia	February 7, 2012	Phase 2
NCT05053425	LanZhou University	Acute Myeloid Leukemia	October 20, 2021	Not Applicable
NCT00436826	EMD Serono Research & Development Institute, Inc.\|EMD Serono	Multiple Sclerosis	November 30, 2006	Phase 2
NCT03318419	Sun Yat-sen University	Acute Lymphoblastic Leukemia	January 1, 2016	Phase 2
NCT03602131	Sichuan University	Hodgkin Lymphoma\|Non-hodgkin Lymphoma	January 1, 2019	Phase 2
NCT03441048	Medical College of Wisconsin	Acute Myeloid Leukemia	May 22, 2018	Phase 1
NCT00002833	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Graft Versus Host Disease\|Leukemia\|Myelodysplastic Syndromes	October 1994	Phase 2
NCT02728050	University of Washington\|National Cancer Institute (NCI)\|Bayer	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm	December 1, 2016	Phase 1\|Phase 2
NCT04679506	Peking University Third Hospital	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	December 2020
NCT00764517	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Indolent Adult Non-Hodgkin Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma	August 2008	Phase 2
NCT02416908	Washington University School of Medicine\|Karyopharm Therapeutics Inc	Acute Myeloid Leukemia	June 16, 2015	Phase 1\|Phase 2
NCT03933215	EMD Serono Research & Development Institute, Inc.\|Merck KGaA, Darmstadt, Germany\|EMD Serono	Multiple Sclerosis	May 21, 2019
NCT00003174	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Leukemia	May 1998	Phase 1
NCT04848974	M.D. Anderson Cancer Center	Secondary Acute Myeloid Leukemia	June 11, 2021	Phase 1\|Phase 2
NCT00019071	National Cancer Institute (NCI)	Brain and Central Nervous System Tumors	March 1995	Phase 1
NCT03491579	University Hospital Inselspital, Berne	AML\|Relapse	December 2018	Phase 1
NCT05578378	The First Affiliated Hospital of Soochow University\|The First People´s Hospital of Changzhou\|Zhongda Hospital\|Suzhou Municipal Hospital	Acute Lymphoblastic Leukemia	January 1, 2022	Phase 2\|Phase 3
NCT00004904	Northwestern University\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders\|Graft Versus Host Disease\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Precancerous+Nonmalignant Condition\|Small Intestine Cancer	October 1999	Phase 1
NCT05466318	Sichuan University	Lymphoma, Large B-Cell, Diffuse\|Lymphoma, T-Cell	July 1, 2022	Phase 3
NCT02921061	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Mixed Phenotype Acute Leukemia\|Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory High Risk Myelodysplastic Syndrome\|Untreated Adult Acute Myeloid Leukemia	November 17, 2016	Phase 1\|Phase 2
NCT03926624	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	November 22, 2019	Phase 3
NCT03963375	Washington University School of Medicine\|EMD Serono	Multiple Sclerosis\|Multiple Sclerosis, Relapsing-Remitting	October 28, 2019	Phase 4
NCT00483067	M.D. Anderson Cancer Center	Leukemia	March 1998	Phase 2
NCT00725985	EMD Serono Research & Development Institute, Inc.\|EMD Serono	Multiple Sclerosis	December 31, 2008	Phase 3
NCT03151876	Sichuan University	Lymphoma	June 12, 2017	Phase 2
NCT04047641	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Blasts 20 Percent or More of Bone Marrow Nucleated Cells\|High Risk Myelodysplastic Syndrome\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory High Risk Myelodysplastic Syndrome	October 22, 2019	Phase 1\|Phase 2
NCT01439750	Milton S. Hershey Medical Center	Mantle Cell Lymphoma	May 2012	Phase 1
NCT01161550	Washington University School of Medicine	Leukemia, Myeloid, Acute	November 2010	Phase 1
NCT00923013	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hairy Cell Leukemia	October 20, 2008	Phase 2
NCT00002805	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	August 1997	Phase 2
NCT02250937	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	October 27, 2014	Phase 2
NCT00641537	EMD Serono Research & Development Institute, Inc.\|EMD Serono	Relapsing-Remitting Multiple Sclerosis	February 29, 2008	Phase 3
NCT05330364	Ge Zheng\|Zhongda Hospital	Acute Myeloid Leukemia	June 1, 2021	Phase 2
NCT00002879	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	November 1996	Phase 2
NCT04861207	Maria Sklodowska-Curie National Research Institute of Oncology\|KCRI	Acute Myeloid Leukemia Myelodysplastic Syndromes	June 30, 2021	Phase 2
NCT00667329	M.D. Anderson Cancer Center	Lymphoma	July 9, 1999	Phase 1
NCT00980395	University of Arizona\|National Cancer Institute (NCI)	Lymphoma\|Mantle Cell Lymphoma\|Indolent Lymphoma\|SLL	July 7, 2009	Phase 2
NCT04196010	University of Washington	Myeloid Neoplasm\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	May 8, 2020	Phase 1
NCT00111345	University Hospital Muenster\|Deutsche Krebshilfe e.V., Bonn (Germany)	Myeloid Leukemia	March 2004	Phase 2\|Phase 3
NCT00053027	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	February 2003	Phase 2
NCT05330377	Ayman H Qasrawi\|Astellas Pharma Inc\|University of Kentucky	Acute Myeloid Leukemia	March 2023	Phase 1
NCT00004762	National Center for Research Resources (NCRR)\|Scripps Clinic\|Office of Rare Diseases (ORD)	Cholangitis, Sclerosing	December 1994	Phase 2
NCT00199017	Johann Wolfgang Goethe University Hospital	Lymphoma, Lymphoblastic	April 2004	Phase 4
NCT03181815	Sun Yat-sen University	Acute Myeloid Leukemia\|Relapse Leukemia	January 1, 2016	Phase 2
NCT03933202	EMD Serono Research & Development Institute, Inc.\|Merck KGaA, Darmstadt, Germany\|EMD Serono	Multiple Sclerosis	July 22, 2019
NCT00003178	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	March 1998	Phase 2
NCT04375631	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Mixed Phenotype Acute Leukemia\|Refractory Myelodysplastic Syndrome\|Refractory Acute Leukemia of Ambiguous Lineage\|Refractory Acute Undifferentiated Leukemia	December 3, 2020	Phase 1
NCT00126321	University Hospital, Bonn	Leukemia, Myelocytic, Acute	November 2004	Phase 2
NCT03745144	Merck KGaA, Darmstadt, Germany	Relapsing Multiple Sclerosis (RMS)	January 17, 2019	Phase 1
NCT03384225	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine\|Changhai Hospital\|Xiangya Hospital of Central South University\|Tongji Hospital\|Wuhan Union Hospital, China\|Chengdu PLA General Hospital\|Tang-Du Hospital\|Fujian Medical University Union Hospital	High Risk Acute Myeloid Leukemia\|Allogeneic Hematopoeitic Stem Cell Transplantation	August 1, 2016	Phase 3
NCT04695080	Queen Mary University of London\|National Institute for Health Research, United Kingdom\|Merck Serono Limited, UK\|Multiple Sclerosis Society of Great Britain & Northern Ireland\|National Multiple Sclerosis Society USA\|Barts & The London NHS Trust	Advanced Multiple Sclerosis\|Progressive Multiple Sclerosis	June 25, 2021	Phase 2\|Phase 3
NCT03384212	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine\|Changhai Hospital\|Xiangya Hospital of Central South University\|Tongji Hospital\|Wuhan Union Hospital, China\|Chengdu PLA General Hospital\|Tang-Du Hospital\|Fujian Medical University Union Hospital	High Risk Acute Myeloid Leukemia\|Allogeneic Hematopoeitic Stem Cell Transplantation	August 1, 2016	Phase 3
NCT00656812	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Hoffmann-La Roche\|Lipomed	Lymphoma of Mucosa-Associated Lymphoid Tissue	May 2008	Phase 2
NCT00198991	Goethe University\|Deutsche Krebshilfe e.V., Bonn (Germany)\|German Federal Ministry of Education and Research	Adult Acute Lymphocytic Leukemia	April 2003	Phase 4
NCT00938366	Merck KGaA, Darmstadt, Germany\|Merck Serono S.A., Geneva	Multiple Sclerosis	January 2008	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 30 mg/mL ( 105.01 mM )

H ₂ O : 10 mg/mL ( 35.00 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5003 mL	17.5015 mL	35.0030 mL
5 mM	0.7001 mL	3.5003 mL	7.0006 mL
10 mM	0.3500 mL	1.7501 mL	3.5003 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 25 mg/mL (87.51 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

Adenosine, 2-chloro-2′-deoxy-

2-Chloro-2′-deoxyadenosine

2-Chloro-2′-deoxy-β-adenosine

2-Chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine

2-Chlorodeoxyadenosine

NSC 105014-F

Cladribine

RWJ 26251

Leustatin

2-CdA

Cladarabine

NSC 105014

CldAdo

Jk 6251

Biodribin

Leustat

(2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

Vero-Cladribine

Mavenclad

Litak